Clinical chemistry 2020 Nov 01
Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification.
Related Questions
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
6
8 Answers
Mednet Member
Medical Oncology · Northwell Health-Lenox Hill Hospital
I would start chemotherapy because of the triple-negative status of the metastasis. This is a patient who initially presented with hormone receptor-positive breast cancer and subsequently developed an isolated bone metastasis that was triple negative. The question of systemic therapy post-localized ...
For patients with metastatic HER2-null breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?
4 Answers
Mednet Member
Medical Oncology · Ohio State University
DAISY trial was a small trial and the outcome was hypothesis-generating rather than practice-changing. With that said, I offer trastuzumab deruxtecan to patients with metastatic breast cancer even if HER2 IHC on biopsy of metastatic disease was 0 but historically, their primary tumor tested at least...